Interventions for treating antibody‐mediated acute rejection in kidney transplant recipients
References
Additional references
Abecassis M, Bartlett ST, Collins AJ, Davis CL, Delmonico FL, Friedewald JJ, et al. Kidney transplantation as primary therapy for end‐stage renal disease: a National Kidney Foundation/Kidney Disease Outcomes Quality Initiative (NKF/KDOQITM) conference. Clinical Journal of The American Society of Nephrology: CJASN2008; Vol. 3, issue 2:471‐80. [MEDLINE: 18256371]
Drachenberg CB, Papadimitriou JC. Endothelial injury in renal antibody‐mediated allograft rejection: a schematic view based on pathogenesis. Transplantation 2013;95(9):1073–83. [MEDLINE: 23370711]
Franco A, Anaya F, Niembro E, Ahijado F, Luno J, Valderrabano F. Plasma exchange in the treatment of vascular rejection. Relationship between histological changes and therapeutic response. Transplantation Proceedings 1987;19(5):3661‐3. [MEDLINE: 3313882]
Gharibi Z, Ayvaci MU, Hahsler M, Giacoma T, Gaston RS, Tanriover B. Cost‐effectiveness of antibody‐based induction therapy in deceased donor kidney transplantation in the United States. Transplantation 2017;101(6):1234‐41. [MEDLINE: 27379555]
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck‐Ytter Y, Alonso‐Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924‐6. [MEDLINE: 18436948]
Guyatt G, Oxman A D, Akl E A, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction‐GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64:383‐94. [MEDLINE: 22818160]
Guerra G, Ciancio G, Gaynor JJ, Zarak A, Brown R, Hanson L, et al. Randomized trial of immunosuppressive regimens in renal transplantation. Journal of the American Society of Nephrology 2011;22(9):1758‐68. [MEDLINE: 21807891]
Haas M, Sis B, Racusen LC, Solez K, Glotz D, Colvin RB, et al. Banff 2013 meeting report: inclusion of c4d‐negative antibody‐mediated rejection and antibody‐associated arterial lesions.[Erratum appears in Am J Transplant. 2015 Oct;15(10):2784 Note: Rangel, Erika [corrected to Rangel, Erika B]; PMID: 26382206]. American Journal of Transplantation 2014;14(2):272–83. [MEDLINE: 24472190]
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60. [MEDLINE: 12958120]
Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Jeannet M, Pinn VW, Flax MH, Winn HJ, Russell PS. Humoral antibodies in renal allotransplantation in man. New England Journal of Medicine 1970;282(3):111‐7. [MEDLINE: 4902226]
Kaposztas Z, Podder H, Mauiyyedi S, Illoh O, Kerman R, Reyes M, et al. Impact of rituximab therapy for treatment of acute humoral rejection. Clinical Transplantation 2009;23(1):63‐73. [MEDLINE: 19200217]
Lee J, Kim BS, Park Y, Lee JG, Lim BJ, Jeong HJ, et al. The effect of bortezomib on antibody‐mediated rejection after kidney transplantation. Yonsei Medical Journal 2015;56(6):1638‐42. [MEDLINE: 26446648]
Lefaucheur C, Nochy D, Andrade J, Verine J, Gautreau C, Charron D, et al. Comparison of combination plasmapheresis/IVIg/anti‐CD20 versus high‐dose IVIg in the treatment of antibody‐mediated rejection. American Journal of Transplantation 2009;9(5):1099‐107. [MEDLINE: 19422335]
Locke JE, Magro CM, Singer AL, Segev DL, Haas M, Hillel AT, et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody‐mediated rejection. American Journal of Transplantation 2009;9(1):231‐5. [MEDLINE: 18976298]
Morgan RD, O'Callaghan JM, Knight SR, Morris PJ. Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta‐analysis. Transplantation 2012;93(12):1179‐88. [MEDLINE: 22660659]
Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. New England Journal of Medicine 1969;280(14):735‐9. [MEDLINE: 4886455]
Roumenina LT, Zuber J, Fremeaux‐Bacchi V. Physiological and therapeutic complement regulators in kidney transplantation. Current Opinion in Organ Transplantation 2013;18(4):421‐9. [MEDLINE: 23838647]
Schieppati A, Remuzzi G. Chronic renal diseases as a public health problem: epidemiology, social, and economic implications. Kidney International ‐ Supplement 2005, (98):S7‐S10. [MEDLINE: 16108976]
Schünemann HJ, Oxman AD, Higgins JP, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Schünemann HJ, Oxman AD, Higgins JP, Deeks JJ, Glasziou P, Guyatt GH. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Smith RN, Kawai T, Boskovic S, Nadazdin O, Sachs DH, Cosimi AB, et al. Chronic antibody mediated rejection of renal allografts: pathological, serological and immunologic features in nonhuman primates. American Journal of Transplantation 2006;6(8):1790‐8. [MEDLINE: 16780551]
Smith RN, Malik F, Goes N, Farris AB, Zorn E, Saidman S, et al. Partial therapeutic response to Rituximab for the treatment of chronic alloantibody mediated rejection of kidney allografts. Transplant Immunology 2012;27(2‐3):107‐13. [MEDLINE: 22960786]
SONG Initiative. The SONG Handbook Version 1.0. songinitiative.org/reports‐and‐publications/2017.
Tanriover B, Zhang S, MacConmara M, Gao A, Sandikci B, Ayvaci MU, et al. Induction therapies in live donor kidney transplantation on tacrolimus and mycophenolate with or without steroid maintenance. Clinical Journal of The American Society of Nephrology: CJASN 2015;10(6):1041‐9. [MEDLINE: 25979971]
Vangelista A, Frasca GM, Nanni Costa A, Stefoni S, Bonomini V. Value of plasma exchange in renal transplant rejection induced by specific anti‐HLA antibodies. Transactions ‐ American Society for Artificial Internal Organs 1982;28:599‐603. [MEDLINE: 6761939]
Waiser J, Budde K, Schutz M, Liefeldt L, Rudolph B, Schonemann C, et al. Comparison between bortezomib and rituximab in the treatment of antibody‐mediated renal allograft rejection. Nephrology Dialysis Transplantation 2012;27(3):1246‐51. [MEDLINE: 21852274]
Webster AC, Ruster LP, McGee R, Matheson SL, Higgins GY, Willis NS, et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD003897.pub3]
